Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Bulb Flat
Contact UsBulb Flat Steel is mainly used in shipbuilding, marine engineering, steel structure engineering, and bridge engineering.Most ships choose ball-flat steel for structural design.
-
FO-Curtain Series (P10.4,P12.5,P15.6,P25,P31.2)(500×1000mm)
Contact UsLED Curtain Display-P10.4, P12.5, P15.6, P25, P31.2
-
Portable 12V&24V Jump Starter with Lithium lron Phosphate
Contact UsJump Starter featuring advanced lithium iron phosphate technology.
-
An ideal climate with Powerful units K48UXR-727P
Contact Us● Powerful units with high cooling and heating capacity
● Lightweight design, intelligent design
● Longer battery life, meeting the need for a full night’s sleep
● Energy saving/lightweight/quiet
● Split structure, bottom mounted
● Energy saving and low consumption, quality assurance
● The company has passed the automotive industry IATF16949 certification
Reviews
There are no reviews yet.